OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons
Juan Yu, Zhanghong Zhao, Yuanyuan Li, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28838-e28838
Open Access | Times Cited: 6
Juan Yu, Zhanghong Zhao, Yuanyuan Li, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28838-e28838
Open Access | Times Cited: 6
Showing 6 citing articles:
Resveratrol-Enhanced Human Neural Stem Cell-Derived Exosomes Mitigate MPP+-Induced Neurotoxicity Through Activation of AMPK and Nrf2 Pathways and Inhibition of the NLRP3 Inflammasome in SH-SY5Y Cells
Tony F. Chan, Yuping Yang, Christopher J.B. Nicol, et al.
Life (2025) Vol. 15, Iss. 2, pp. 294-294
Open Access | Times Cited: 1
Tony F. Chan, Yuping Yang, Christopher J.B. Nicol, et al.
Life (2025) Vol. 15, Iss. 2, pp. 294-294
Open Access | Times Cited: 1
The role of quercetin in NLRP3-associated inflammation
Jiaqi Wu, Tongtong Lv, Yü Liu, et al.
Inflammopharmacology (2024)
Closed Access | Times Cited: 5
Jiaqi Wu, Tongtong Lv, Yü Liu, et al.
Inflammopharmacology (2024)
Closed Access | Times Cited: 5
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer’s Disease and Parkinson’s Disease
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1203-1204
Closed Access | Times Cited: 1
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1203-1204
Closed Access | Times Cited: 1
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson’s Disease or Frontotemporal Dementia
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2083-2084
Open Access
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2083-2084
Open Access
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2099-2100
Open Access
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2099-2100
Open Access
Bioengineered Exosomes: Cellular Membrane-Camouflaged Biomimetic Nanocarriers for Parkinson’s Disease Management
Maham Afzal, Huma Hameed, Ana Cláudia Paiva‐Santos, et al.
European Journal of Pharmacology (2024) Vol. 987, pp. 177199-177199
Closed Access
Maham Afzal, Huma Hameed, Ana Cláudia Paiva‐Santos, et al.
European Journal of Pharmacology (2024) Vol. 987, pp. 177199-177199
Closed Access
